US Stock Market Move | AstraZeneca PLC Sponsored ADR (AZN.US) rose more than 2% as Imfinzi was approved for a new indication in the EU.

On Friday, Astrazeneca PLC Sponsored ADR (AZN.US) rose more than 2% to $72.45. On the news front, on May 27, Astrazeneca PLC Sponsored ADR announced that Imfinzi (durvalumab) has received approval from the European Union for specific indications: durvalumab in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by durvalumab as adjuvant monotherapy after radical cystectomy, for the treatment of muscle-invasive bladder cancer (MIBC) in adult patients.